Improved outcomes in inflammatory lung disease with remestemcel-l published in respiratory research journal

New york, may 25, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the peer-reviewed journal respiratory research has published results showing that mesoblast's mesenchymal stromal cell (msc) product candidate remestemcel-l significantly improved respiratory and functional clinical outcomes in patients with chronic obstructive pulmonary disease (copd) and elevated levels of the inflammatory biomarker c-reactive protein (crp). patients with copd and elevated crp levels have increased rates of hospitalization and death.1 these results provide further rationale for potential use of remestemcel-l in inflammatory lung diseases, including covid-19 acute respiratory distress syndrome (ards).
MESO Ratings Summary
MESO Quant Ranking